Adjuvant treatment with dabrafenib and trametinib may be more effective than observation or adjuvant treatment with a PD-1 inhibitor in patients with stage IIIA melanoma, according to retrospective findings published in Annals of Oncology.
Health Professionals
Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk
Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.